AOECS is dedicated to support research on coeliac disease and dermatitis herpetiformis Duhring and is involved in several projects aimed at improving diagnosis and treatment of these conditions.




The objective of this EU-funded project is to obtain an instrument that will be a low-cost non-invasive intelligent diagnosis system that can be present at point of care, such as a doctor’s surgery which will bring benefits to patients and healthcare professionals.

The applications of the proposed integrated micro system and its individual modules for coeliac disease diagnosis, monitoring and management are multiple. The analysis of the HLA-DQ2 & 8 genes will provide information on the genetic predisposition of an individual, while serum IgA and IgG indicate antibodies associated with gluten in the diet.

For more information, please visit the CD-Medics webpage.



The project is a European multicentre study funded by a grant from the European Union (FP6-2005-FOOD-4B-36383). The study involves 17 partners of 11 countries: 13 clinical centres, 3 industrial companies and AOECS, the representative of coeliac patients.


The study investigated the influence of infant feeding on the risk of developing CD. The hypothesis is that by exposing infants to small quantities of gluten while they are still being breast-fed to possibly induce tolerance to gluten thus reducing the risk for CD in genetically susceptible individuals.

For more information, please visit the PreventCD website.



The acronym stands for Prospective Celiac Disease Diagnostic Evaluation.

The reference standard for the diagnosis of Celiac Disease (CD) is based on estimates using mostly retrospective evaluations or data from single-center studies. Therefore, the working group of ESPGHAN on the diagnostic criteria of CD felt obliged to evaluate the new criteria on a large pediatric population in different countries and settings including a broad range of symptomatic and asymptomatic children which are referred for further work up because of a positive test result for antibodies against tissue transglutaminase. The ProCeDE study aims to provide prospective data to assure that this diagnostic procedure is valid also in clinical practice with positive predictive value above 99%. Furthermore, interobserver variability for histology and inter-test variability will be assessed and the impact of HLA-typing on diagnosis will be evaluated.

For more information, please read the project summary.


Center Watch logo


CenterWatch provides clinical trials information for both clinical research professionals and patients. Offering professional, educational and informative services and resources from news and analysis on the industry to trial listings seeking study volunteers.